logo
Plus   Neg
Share
Email

Array BioPharma Says BRAFTOVI + MEKTOVI + Cetuximab Meet Primary Endpoints

Array BioPharma Inc. (ARRY) reported positive results from the interim analysis of the Phase 3 BEACON CRC trial evaluating the combination of BRAFTOVI or encorafenib, a BRAF inhibitor, MEKTOVI or binimetinib, a MEK inhibitor, and ERBITUX or cetuximab, an anti-EGFR antibody or BRAFTOVI Triplet, in patients with BRAFV600E-mutant metastatic colorectal cancer or mCRC, following one or two prior lines of therapy.

The company stated that the trial met both primary endpoints of confirmed objective response rate or ORR, as assessed by Blinded Independent Central Review or BICR, and overall survival or OS.

The company plans to submit these results of the BEACON CRC trial for marketing approval in the second half of 2019.

The triplet combination of BRAFTOVI, MEKTOVI and ERBITUX for the treatment of patients with BRAFV600E-mutant mCRC is investigational and not approved by the FDA.

For comments and feedback contact: editorial@rttnews.com

Business News

Editors Pick
Snap Inc. (SNAP) Tuesday reported a narrower loss for the second quarter that also was better than Wall Street's expectations, as revenues surged on strong user growth. The company issued a strong revenue guidance for the current quarter, sending its shares up 10 percent in after-hours trade. California-based... Shares of Texas Instruments Inc. (TXN) gained over 6% in extended trading session on Tuesday after the analog chip maker reported a second-quarter profit and revenue that trumped analysts' expectations. The company also issued a strong financial outlook for the third quarter. Dallas, Texas-based Texas... Justin Sun, the entrepreneur who founded the cryptocurrency platform TRON, has postponed his charity lunch with billionaire investor Warren Buffett due to ill health. "TRON Foundation announces postponement of Warren Buffett lunch, press conferences after founder Justin Sun falls ill with kidney stones....
Follow RTT